Moderna Vaccine: US-based Corona Vaccine Company, May begin the Third Phase of Clinical Trials in July
Moderna, a US-based Corona vaccine company, may begin the third phase of clinical trials of the Corona vaccine in July. World Health Organization (WHO) Chief Scientist Soumya Swaminathan says that AstraZeneca's Experimental Covid-19 vaccine is at the forefront. America's Moderna Therapeutics biotechnology company is involved in making Corona's vaccine. The company aims to create a vaccine that will increase people's immunity.
Company has Prepared 100 Microgram Doses of Vaccine
According to investigators at the University of Chicago, Illinois, an earlier report said that late-stage trials of a vaccine involving 30,000 participants had been delayed due to changes in the study plan. The company has prepared 100 microgram doses of vaccine for the last phase. Apart from this, the company is preparing to deliver about 50 crore doses every year.
The test was scheduled to begin on July 9. Previously Soumya Swaminathan has said about the AstraZeneca vaccine, "The stage he is on and advanced, I think he is at the forefront." Oxford and AstraZeneca Plc. The vaccine AZD1222 (formerly ChAdOx1 nCov-19) is in the final stage of the clinical trial. This first vaccine to reach this stage will now be given to 10,260 people. Its trial is also being done in Britain, South Africa and Brazil.
Meanwhile, there has been talking of speeding up trials in India on the Corona vaccine. Aiming to launch India's first indigenous COVID-19 vaccine by 15 August, the Indian Council of Medical Research (ICMR) has called for expediting the trial of Kovaxin, a vaccine to be developed in collaboration with Bharat Biotech.
Like and Follow us on :